Psychosocial correlates of intention to undergo prophylactic oophorectomy among women with a family history of ovarian cancer

Preventive Medicine

Volumn 37, Issue 5, 2003, Pages 424-431

  Fang, Carolyn Y ^a   Miller, Suzanne M ^a   Malick, John ^a   Babb, James ^a   Engstrom, Paul F ^a   Daly, Mary B ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Benefits; Ovarian cancer; Perceived risk; Prophylactic oophorectomy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DISTRESS SYNDROME; FAMILY HISTORY; FEMALE; HUMAN; INFORMATION PROCESSING; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; OVARIECTOMY; OVARY CARCINOMA; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOSOCIAL DISORDER; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0142152307     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-7435(03)00163-4     Document Type: Article

References (48)

1. American Cancer Society. Cancer facts and figures, 2002. Atlanta, GA, 2002.
2. Rosenthal A., Jacobs I. Ovarian cancer screening. Semin Oncol. 25:1998;315-325.
3. Hensley M.L., Castiel M., Robson M.E. Screening for ovarian cancer what we know, what we need to know . Oncology. 14:2000;1-18.
4. Hartge P., Whittemore A.S., Itnyre J., McGowan L., Cramer D.W., Group T.C.O.C. Rates and risks of ovarian cancer in subgroups of white women in the United States. Obstet Gynecol. 84:1994;760-764.
5. Stratton J.R., Pharoah P., Smith S.K., et al. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol. 105:1998;493-499.
6. Berchuck A., Schildkraut J., Marks J., Futreal P. Managing hereditary ovarian cancer risk. Cancer. 86:1999;2517-2524.
7. Liede A., Karlan B.Y., Baldwin R.L., Platt L.D., Kuperstein G., Narod S.A. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol. 20:2002;1570-1577.
8. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 62:1998;676-689.
9. Rozario D., Brown I., Fung M.F.K., Temple L. Is incidental prophylactic oopherectomy an acceptable means to reduce the incidence of ovarian cancer? Am J Surg. 173:1997;495-498.
10. Kauff N.D., Satagopan J.M., Robson M.E., Scheuer L., Hensley M., Hudis C.A., Ellis N.A., Boyd J., Borgen P.I., Barakat R.R., Norton L., Castiel M., Nafa K., Offit K. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 346:2002;1609-1615.
11. Rebbeck T.R., Lynch H.T., Neuhausen S.L., Narod S.A., van't Veer L., Garber J.E., Evans G., Isaacs C., Daly M.B., Matloff E., Olopade O.I., Weber B.L. The prevention and observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 346:2002;1616-1622.
12. Rebbeck T., Levin A., Eisen A., Snyder C., Watson P., Cannon-Albright L., Isaacs C., Olopade O., Garber J.E., Godwin A., Daly M.B., Narod S., Neuhausen S., Lynch H.T., Weber B. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 91:1999;1475-1479.
13. Miller S.M., Fang C.Y., Manne S.L., Engstrom P.F., Daly M.B. Decision making about prophylactic oophorectomy among at-risk women Psychological influences and implications . Gynecol Oncol. 75:1999;406-412.
14. Piver M.S., Jishi M., Tsukada Y., Nava G. Primary peritoneal carcinoma after prophylactic oopherectomy in women with a family history of ovarian cancer. Cancer. 71:1993;2751-2755.
15. Eltabbakh G.H., Piver M.S. Extraovarian primary peritoneal carcinoma. Oncology. 12:1998;813-819.
16. Hallowell N. "You don't want to lose your ovaries because you think" 'I might become a man.' Women's perceptions of prophylactic surgery as a cancer risk management option. Psychooncology. 7:1998;263-275.
17. Kritz-Siverstein D., Barrett-Connor E., Wingard D.L. Hysterectomy, oophorectomy and heart disease risk factors in older women. Am J Public Health. 87:1997;676-680.
18. Fry A., Busy-Earle C., Rush R., Cull A. Prophylactic oophorectomy versus screening Psychosocial outcomes in women at increased risk of ovarian cancer . Psychooncology. 10:2001;231-241.
19. Fry A., Rush R., Busby-Earle C., Cull A. Deciding about prophylactic oophorectomy what is important to women at increased risk of ovarian cancer? Prev Med. 33:2001;578-585.
20. Hallowell N. A qualitative study of the information needs of high-risk women undergoing prophylactic oopherectomy. Psychooncology. 9:2000;486-495.
21. Meiser B., Tiller K., Gleeson M.A., Andrews L., Robertson G., Tucker K. Psychological impact of prophylactic oophorectomy in women at increased risk for ovarian cancer. Psychooncology. 9:2000;496-503.
22. Drummond A. Surveys. Clinical rehabilitation. 4:1990;255-259.
23. Hurley K.E., Miller S.M., Costalas J.W., Gillespie D., Daly M.B. Anxiety/uncertainty reduction as a motivation for interest in prophylactic oophorectomy in women with a family history of ovarian cancer. J Women's Health Gender-Based Med. 10:2001;189-199.
24. Meiser B., Butow P., Barratt A., Friedlander M., Gattas M., Kirk J., Suthers G., Walpole I., Tucker K. Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecol Oncol. 75:1999;122-129.
25. Wagner T., Moslinger R., Langbauer G., Ahner R., Fleischmann E., Auterith A., Friemann A., Helbich T., Zelinski C., Pittermann E., Seifert M., Oefner P. Attitude towards prophylactic surgery and effects of genetic counseling in families with BRCA mutations. B J Cancer. 82:2000;1249-1253.
26. Tiller K., Meiser B., Butow P., Clifton M., Thewes B., Friedlander M., Tucker K. Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer a prospective study . Gynecol Oncol. 86:2002;212-219.
27. Miller S.M., Shoda Y., Hurley K. Applying cognitive-social theory to health-protective behavior Breast self-examination in cancer screening . Psychol Bull. 119:1996;70-94.
28. Miller S.M., Fang C.Y., Diefenbach M.A., Bales C.B. Tailoring psychosocial interventions to the individual's health information processing style the influence of monitoring versus blunting in cancer risk and disease . Baum A., Andersen B. Psychosocial interventions for cancer. 2001;343-362 American Psychological Association, Washington, DC.
29. Lerman C., Daly M., Masny A., Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol. 12:1994;843-850.
30. Schwartz M.D., Lerman C., Miller S.M., Daly M., Masny A. Coping disposition, perceived risk, and psychological distress among women at increased risk for ovarian cancer. Health Psychol. 14:1995;232-235.
31. Hay J.L., Ostroff J.S., Cruz G.D., LeGeros R.Z., Kenigsberg H., Franklin D.M. Oral cancer risk perception among participants in an oral cancer screening program. Cancer Epidemiol Biomark Prev. 11:2002;155-158.
32. McNair D.M., Lorr M., Droppleman L.F. Manual for the profile of mood states. 1971;Educational and Industrial Testing Service, San Diego, CA.
33. Lerman C., Narod S.A., Schulman K., Hughes C., Gomez-Caminero A., Bonney G., Gold K., Trock B., Main D., Lynch J., Fulmore C., Snyder C., Lemon S.J., Conway T., Tonin P., Lenoir G., Lynch H. BRCA1 testing in families with hereditary breast-ovarian cancer. JAMA. 275:1996;1885-1892.
34. Meijers-Heijboer E., Verhoog L., Brekelmans C., Seyaeve C., Tilanus-Linthorst M., Wagner A., Dukel L., Devilee P., van den Ouweland A., van Geel A., Klijn J. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutations. Lancet. 355:2000;2015-2020.
35. Meiser B., Butow P., Friedlander M., Schnieden V., Gattas M., Kirk J., Suthers G., Haan E., Tucker K. Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. J Clin Oncol. 18:2000;2250-2257.
36. Stefanek M.E., Helzlsouer K.J., Wilcox P.M., Houn F. Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med. 24:1995;412-419.
37. Lodder L.N., Frets P.G., Trijsburg R.W., Meijers-Heijboer E., Klijn J.G.M., Seynaeve C., van Geel A., Tilanus M.M., Bartels C.C., Verhoog L.C., Brekelmans C.T., Burger C.W., Niermeijer M.F. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2 emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery) . Breast Cancer Res Treat. 73:2002;97-112.
38. Fang C.Y., Miller S.M., Daly M.B., Hurley K. The influence of coping style and risk perceptions on decisions to undergo prophylactic oophorectomy among FDRs. Psychol Health. 17:(3):2002;365-376.
39. Hallowell N., Jacobs I., Richards M., Mackay J., Gore M. Surveillance or surgery? A description of the factors that influence high risk premenopausal women's decisions about prophylactic oophorectomy. J Med Genet. 38:2001;683-691.
40. Eisen A., Rebbeck T., Wood W., Weber B. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol. 18:2000;1980-1995.
41. Lodder L.N., Frets P.G., Trijsburg R.W., Meijers-Heijboer E.J., Klijn J.G.M., Duivenvoorden H.J., Tibben A., Wagner A., van der Meer C.A., Devilee P., Cornelisse C.J., Niermeijer M.F. other members of the Rotterdam/Leiden Genetics Working Group. Presymptomatic testing for BRCA1 and BRCA2 how distressing are the pre-test weeks? J Med Genet. 36:1999;906-913.
42. Ajzen I. Nature and operation of attitudes. Ann Rev Psychol. 52:2000;27-58.
43. Durfy S.J., Bowen D.J., McTiernan A., Sporleder J., Burke W. Attitudes and interest in genetic testing for breast and ovarian cancer susceptibility in diverse groups of women in western Washington. Cancer Epidemiol Biomarkers Prev. 8:1999;369-375.
44. Myers R.E., Hyslop T., Jennings-Dozier K., Wolf T.A., Burgh D.Y., Dieh J.A., Lerman C., Chodak G.W. Intention to be tested for prostate cancer risk among African-American men. Cancer Epidemiol Biomarkers Prev. 9:2000;1323-1328.
45. Bottorff J.L., Ratner P.A., Balneaves L.G., Richardson C.G., McCullum M., Hack T., Chalmers K., Buxton J. Women's interest in genetic testing for breast cancer risk the influence of sociodemographics and knowledge . Cancer Epidemiol Biomarkers Prev. 11:2002;89-95.
46. Morris K.T., Johnson N., Krasikov N., Allen M., Dorsey P. Genetic counseling impacts decision for prophylactic surgery for patients perceived to be at high risk for breast cancer. Am J Surg. 181:2001;431-433.
47. Begg C.B. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst. 94:2002;1221-1226.
48. Burke W., Austin M.A. Genetic risk in context Calculating the penetrance of BRCA1 and BRCA2 mutations . J Natl Cancer Inst. 94:2002;1185-1187.